评估GLP-1受体激活剂与局部晚期直肠癌的全新辅助疗法相结合的影响
Hugo C Temperley1,2,3, Matthew Coalter4, Ben Creavin3,5
1Department of Radiology, St. James's Hospital, Dublin, Ireland.
The British journal of surgery
|March 10, 2026
概括
对直肠癌的全新辅助疗法 (TNT) 显示出有前途. 将其与葡萄糖类-1受体激动剂 (GLP-1 RAs) 结合使用,可以通过向代谢因素和炎症来改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 代谢综合征是代谢综合征的一种.
背景情况:
- 总的新辅助疗法 (TNT) 是直肠癌的标准,改善了病理完整反应和生存率.
- 类似葡萄糖类-1受体激动剂 (GLP-1 RAs) 在减肥,代谢调节方面具有好处,并具有抗炎性质.
- 观察数据表明GLP-1RA可能会降低与肥胖有关的癌症的发生率,包括结直肠癌.
研究的目的:
- 审查在局部晚期直肠癌中将GLP-1RA与TNT结合的生物基础.
- 探索这种组合疗法的潜在治疗益处.
- 评估GLP-1RA对瘤生物学和治疗耐受性的影响.
主要方法:
- 临床前和临床数据的叙述性综述.
- 检查GLP-1RA对内脏脂肪,胰岛素抵抗和全身炎症的影响.
- 分析GLP-1诱导的代谢变化如何影响化疗有效性和瘤治疗结果.
主要成果:
- GLP-1RA可能调节瘤微环境和与癌症治疗相关的系统因素.
- 由于代谢和抗炎作用,有可能改善化疗的耐受性和疗效.
- 有证据表明,可能会提高外科手术和长期瘤学结果.
结论:
- 将GLP-1RA与TNT结合起来是治疗直肠癌的一个有希望的策略.
- 需要进一步的研究来验证这些发现,特别是在代谢敏感的患者群体中.
- 这种方法可能为改善直肠癌治疗结果提供新的治疗途径.
相关概念视频
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
836
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
836